James Hayden spent his days in Building 7, a squat, windowless block on the periphery of the DARPA campus. Far enough from the main gates to discourage walk-ins, close enough for the funding to keep flowing. The projects inside shifted names like shadows—today's breakthrough was tomorrow's discontinued line item. Lower levels required fresh keycards every quarter. Survival depended on how convincingly you could reframe the work in quarterly reports.

He was a lab tech, not a principal investigator. No PowerPoint decks for generals, no closed-door briefings. He calibrated environmental chambers, ran stability assays, pressed tablets that looked like any over-the-counter painkiller but weren't. The program had no public name. Internally, it rotated through euphemisms. On his task list it was always the same: Cognitive Load Mitigation – Phase II.

The compound reduced neural interference—quieted the mental static that drowned focus. In trials, subjects reported unusual clarity, effortless concentration. Side effects were... under discussion when the program was sunset.

The dismissal came on a Thursday. A curt meeting invite from a compliance officer he'd met once. Strategic realignment. No fault found. His badge deactivated at 17:00. Security walked him to the exit with a cardboard box containing a coffee mug, three binders, and nothing classified.

Thirty pills had already been logged as "transferred pending destruction." Inventory audits moved slowly. The amber bottle ended up in his messenger bag.

He didn't go home. He wandered until he reached the Brightside Café, a narrow storefront he'd passed hundreds of times without entering. Plain wooden tables, unchanging chalkboard menu, no screens. He ordered black coffee, paid cash, chose the chair against the wall with a clear view of the door. Unemployment didn't feel real yet. It felt like a shift with no protocol.

The pills stayed in the bag.

He returned the next day. And the day after. On the fourth morning, during the mid-morning lull, she set his coffee down without calling out an order.

Younger than he'd guessed from across the room. Dark hair pulled into a loose knot, violet streak catching the light when she tilted her head. Green eyes, steady and unhurried. Her face held an asymmetry that made every expression vivid—small lopsided smile when something amused her, one brow lifting higher than the other when she was skeptical.

"You're becoming a regular," she said.

"Apparently."

"James, right?"

He nodded. "And you?"

"Chloe, "Looking for something?" she asked.

"Recently unemployed."

"Don't vanish," she said.

He hadn't planned to.

That night the numbers refused to improve. Severance would stretch a few months if he was careful. Rent, utilities, insurance—the invisible deductions that had once run on autopilot now loomed. Job alerts arrived; he applied to two contract postings that matched his skill set. Responses were polite and distant.

At home the amber bottle migrated from the freezer to the cabinet above the sink. Visibility changed things. Even if he never opened it, the possibility needed to be seen.

Logistics mattered. You couldn't simply offer a stranger a pill. People required a narrative they could accept, a reason that fit their self-image. A barista occupied ideal territory: familiar face, low stakes, routine trust. Cups changed hands without scrutiny.

Chloe fit the profile perfectly. Curious about chemistry. Intelligent enough to appreciate the science. Isolated enough in her routine that an anomaly might intrigue rather than alarm.

The next visit he observed without staring—timing how long named drinks sat on the pickup counter, how customers drifted away. When she brought his refill, she lingered.

"You're quieter today," she noted.

"So are you."

She leaned against the back of the chair opposite him, arms crossed loosely.

"When I was working," he said, "we studied attention. Why it fragments."

"Burnout?"

"Interference. Background noise in the brain."

"And the fix?"

"Stimulants, usually. Which trade one problem for another."

"Yours?"

"Subtler. Reduces the noise instead of forcing output higher."

"Does it work?"

"In controlled settings," he said, "the data were promising."

That much was accurate.

"I have a sample," he added. "If you ever wanted to try it. For study purposes."

Her eyes narrowed slightly—not suspicion, assessment.

"That's... not a standard offer."

"It's not illegal. And I wouldn't suggest it if I believed it unsafe."

He left out the discontinued status. The skipped Phase III. The fact that sharpened focus had been only one observed outcome.

"Think about it," he said.

She nodded and returned to the counter.

He didn't push. When she asked questions later—stress pathways, attention networks, cognitive bottlenecks—he answered clinically, precisely. He told himself this was about unfinished work. The research deserved continuation. The compound deserved testing beyond sterile lab conditions.

When she sat across from him again, her gaze was level.

"I've been thinking," she said.

He waited.

"If it's real, I want to understand how it works."

"It is."

"My shift ends at eight."

"I'll be available."